Business
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with
About this update from Oculis Holding Ag
[{"type":"text","content":"ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with topline results expected in June 2026A non-invasive topical treatment for diabetic macular edema (DME) has the potential to address significant unmet needs for early treatment intervention and for inadequate responders to the current standard of care2-4OCS-01 aims to transform the treatment paradigm as the first topical treatment for DME, a leading cause of vision loss in the working-age population in most developed countries1 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced completion of the final patient visit in the OCS-01 Phase 3 DIAMOND program in diabetic macular edema (DME). Oculis expects to report topline results in June 2026. Riad Sherif, M.D., Chief Executive Officer of Oculis, stated, “The completion of the last patient visit in both DIAMOND Phase 3 trials represents a pivotal milestone as we advance towards anticipated topline results in June. This achievement reflects our commitment to advancing OCS-01 as a potential first-in-class eye drop therapy for DME, a leading cause of blindness in working-age adults. With multiple catalysts on the horizon across our late-stage portfolio, including the ongoing PIONEER registrational program evaluating Privosegtor in optic neuropathies and PREDICT-1, the first genotype-based registrational trial to drive precision medicine in dry eye disease, with Licaminlimab, Oculis continues to execute on its mission to deliver transformative innovations that address critical unmet needs in ophthalmology and neuro-ophthalmology.” Arshad M. Khanani, M.D., M.A, FASRS, DIAMOND Program Steering Committee Chairperson, Oculis Board of Directors member, Scientific Advisory Board Chair of Retina and Director of Clinical Research at Sierra Eye Associates, added, “DME continues to pose a major challenge in clinical practice, with many patients inadequately served by current therapies due to high treatment burden and sub-optimal response. A non-invasive topical option like OCS-01 could significantly reshape how DME is managed. This is especially important for patients with mil...